Benzinga | Mar 12, 2021 08:03AM EST

AgeX Therapeutics Reports Online Publication Of Data Related To Regeneration, Aging, Cancer In bioRxiv

AgeX Therapeutics, Inc. ((&ldquo, AgeX&rdquo, , NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today the online publication of data relating to regeneration, aging, and cancer in bioRxiv. The paper titled "Differential Expression of ?, ?, and ? Protocadherin Isoforms During Differentiation, Aging, and Cancer" presents for the first time data relating to mechanisms cells may use in the process of regeneration. The paper discloses alterations in certain genes that may prevent regeneration from occurring in adult humans. It also provides evidence that the family of genes may be involved in a wide array of human cancers.

"We believe these results have significant importance for researchers working not only in the field of aging research, but the field of cancer research as well," said Michael D. West, PhD, CEO of AgeX. "As a result, we published this data as a non-peer reviewed preprint to accelerate the timeline during which other scientists can see and test the results in their own laboratories. We plan to implement the findings in our induced Tissue Regeneration (iTR) program, and as a result, have filed a series of relevant patent applications. We plan to publish the results at a later time in a peer-reviewed format."

Authors on the paper include: Michael D. West, Ivan Labat, Jie Li, Pam Sim, Jeffrey Janus, and Hal Sternberg of AgeX; Hayley Mangelson, Shawn Sullivan, and Ivan Liachko of Phase Genomics, Inc.; Paul Labhart, Maddy Craske, and Brian Egan of Active Motif, Inc.; Karen B. Chapman of Eclipse Bioinnovations, Inc.; Nafees N. Malik of Juvenescence Ltd.; and Dana Larocca of DC Biotechnology. The article is available for viewing at https://www.biorxiv.org/content/10.1101/2021.03.07.434314v1.full. A video explaining the results is available for viewing at https://vimeo.com/522148118.